Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches

? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neurology at Brigham and Women’s Hospital in Boston — who’s specialized in antigen-specific tolerance — AnTolRx has been working on a pipeline of immune tolerance therapies for autoimmune and inflammatory ailments. The biotech is picking up an unspecified upfront payment in the deal.

? As a group of industry vets gather at Secura Bio to commercialize cancer therapies around the world, Athyrium Capital Management has jumped in to provide the funds th

Click to view original post